BBIO
HEALTHCAREBridgeBio Pharma Inc
AI Insight
What's Moving BBIO Today?
No stock-specific AI insight has been generated for BBIO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$41.80$84.94
$68.63
Fundamentals
Market Cap$13.5B
P/E Ratio—
EPS$-3.74
Dividend Yield—
Dividend / Share—
ROE-1,790.0%
Profit Margin-124.4%
Debt / Equity—
Trading
Volume2.5M
Avg Volume (10D)—
Shares Outstanding195.9M
BBIO News
28 articles- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jun 23, 2026
- BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026Yahoo Finance·Jun 22, 2026
- DKSH Enters Strategic Distribution Partnership with BridgeBio to Support Regulatory Evaluation and Potential Patient Access to Transthyretin Stabilizer for ATTR-CM in Selected Asia Pacific MarketsYahoo Finance·Jun 11, 2026
- BridgeBio Pharma(BBIO.US) Officer Sells US$5.41 Million in Common StockMoomoo·Jun 8, 2026
- Here Are Wednesday’s Top Wall Street Analyst Research Calls: Boyd Gaming, Chipotle Mexican Grill, Conagra, Dollar General, MGM Resorts International, Omnicom Group, Yum! Brands, and More247 Wall St·Jun 3, 2026
- Yum! Brands upgraded, Chipotle downgraded: Wall Street's top analyst callsYahoo Finance·Jun 3, 2026
- Does FDA Priority Review for First LGMD Therapy Change The Bull Case For BridgeBio Pharma (BBIO)?Yahoo Finance·Jun 1, 2026
- Allogene CEO to step down; Agios drug fails key testBiopharmadive·May 29, 2026
- BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9Yahoo Finance·May 27, 2026
- Intel downgraded, Marvell upgraded: Wall Street's top analyst callsYahoo Finance·May 26, 2026
- BBIO (NASDAQ: BBIO) trust sells repeated 20,000-share blocks under 10b5-1Stock Titan·May 22, 2026
- Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t a Slam Dunk247 Wall St·May 19, 2026
- StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst callsYahoo Finance·May 19, 2026
- Encaleret NDA, Acoramidis Progress, and Buyback Could Be A Game Changer For BridgeBio (BBIO)Simply Wall Street·May 15, 2026
- How Encaleret’s NDA and New Acoramidis Milestones Could Reframe BridgeBio Pharma (BBIO) Investors’ OutlookYahoo Finance·May 15, 2026
- BridgeBio Pharma stock (US10806X1028): Pipeline progress in rare diseasesAD HOC NEWS·May 15, 2026
- BridgeBio Files FDA NDA for Encaleret in ADH1TipRanks·May 14, 2026
- Evercore ISI Retains an “Outperform Rating” on BridgeBio Pharma, Inc. (BBIO)Yahoo Finance·May 13, 2026
- BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline LaunchesMarketbeat·May 13, 2026
- BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trialPharmaceutical-technology·May 12, 2026
- Rare calcium disorder treatment encaleret heads to FDA reviewStock Titan·May 12, 2026
- BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1Yahoo Finance·May 12, 2026
- Analysts Are Updating Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Estimates After Its First-Quarter ResultsYahoo Finance·May 11, 2026
- Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart FailureYahoo Finance·May 11, 2026
- BridgeBio Brazil Approval Expands BEYONTTRA Reach While Valuation Signals UpsideYahoo Finance·May 9, 2026
- BridgeBio (BBIO) Q1 2026 Earnings TranscriptMotley Fool·May 8, 2026
- BridgeBio Pharma Announces $500 Million Stock Repurchase ProgramTipRanks·May 7, 2026
- Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54GlobeNewswire Inc.·Mar 30, 2026
All 28 articles loaded
Price Data
Open$68.57
Previous Close$68.92
Day High$69.90
Day Low$68.03
52 Week High$84.94
52 Week Low$41.80
52-Week Range
$41.80$84.94
$68.63
Fundamentals
Market Cap$13.5B
P/E Ratio—
EPS$-3.74
Dividend Yield—
Dividend / Share—
ROE-1,790.0%
Profit Margin-124.4%
Debt / Equity—
Trading
Volume2.5M
Avg Volume (10D)—
Shares Outstanding195.9M
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—